Quantcast
Last updated on April 16, 2014 at 6:17 EDT

Latest Immunoglobulin E Stories

2014-03-19 16:23:41

Conference call to be held today at 4:30 p.m. EDT MONROVIA, Calif., March 19, 2014 /PRNewswire/ -- Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today reported financial results for the fourth quarter and full year ended December 31, 2013 and provided a review of business highlights. "We are very pleased that Xencor now has five clinical...

2014-03-01 12:20:30

For U.S. Media Only RIDGEFIELD, Conn., March 1, 2014 /PRNewswire/ -- Boehringer Ingelheim today presented data from Phase 3 studies of tiotropium delivered via the Respimat(®) inhaler in mild, moderate and severe asthma patients at the 2014 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting in San Diego. Tiotropium is being studied to determine its efficacy and safety in treating asthma patients and is not currently approved for this indication. The first results...

2013-12-09 08:30:23

LOVELAND, Colo., Dec. 9, 2013 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA, "Heska"), the leading provider of serum IgE testing for companion animals, announced today a new breakthrough in this growing animal health category. "Heska scientists have significantly improved the sensitivity of IgE detection afforded by our proprietary ALLERCEPT(®) technology," commented Michael McGinley, Heska's President of Pharmaceuticals and Biologicals. "This new, unprecedented level of...

2013-11-07 12:28:07

TSX Venture: QPT EDMONTON, Nov. 7, 2013 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, announces the presentation of a late-breaking abstract at the 28(th) Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 9, 2013 in Maryland, U.S. The work was jointly developed by Stanford University, AIT Strategies and Quest as continuation of...

Bee Sting Allergies Could Be Defense Mechanism
2013-10-25 05:04:12

[ Watch the Video: The Evolution Of An Allergy ] redOrbit Staff & Wire Reports - Your Universe Online While bee stings could be fatal to those who are allergic to the insect’s venom, that type of adverse biological reaction is actually the body’s attempt to protect a person from potentially deadly toxins. Writing in Wednesday’s edition of the journal Immunity, scientists from the Stanford University School of Medicine and their colleagues describe how they injected mice...

2013-04-08 20:22:10

TSX Venture: QPT EDMONTON, April 8, 2013 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has recently signed an exclusive license agreement with University of California at Los Angeles to develop and market anti-PSA IgE technology for the treatment of cancer. The technology was developed by Professor Manuel Penichet and Dr. Tracy...

2013-02-25 13:42:25

For expectant moms who may contemplate the pros and cons of natural child birth or Caesarian section, a Henry Ford Hospital study suggests that C-section babies are susceptible to developing allergies by age two. Researchers found that babies born by C-section are five times more likely to develop allergies than babies born naturally when exposed to high levels of common allergens in the home such as those from dogs, cats and dust mites. The study is being presented Sunday at the...

Asthma Drug Found Effective In Treatment Of Chronic Hives, Itchiness
2013-02-25 08:57:48

Lawrence LeBlond for redOrbit.com - Your Universe Online Though not the most common occurrence, researchers do sometimes discover drugs marketed for one particular disease, disorder or illness can work well in treating a totally different condition. One recent discovery was that of a popular diabetes drug that showed promise in treating ovarian cancer. Another--not so recent--discovery was of the antidepressant drug Wellbutrin that proved to be effective in helping smokers kick the habit....

2013-02-24 12:20:31

- Phase III study published in NEJM today and to be presented tomorrow met primary endpoint in moderate-to-severe chronic idiopathic urticaria (CIU) EAST HANOVER, N.J., Feb. 24, 2013 /PRNewswire/ -- Late-breaking results from ASTERIA II, a Phase III placebo-controlled study, showed positive results in patients with moderate to severe chronic idiopathic urticaria (CIU), referred to as chronic spontaneous urticaria (CSU) outside the United States, who remained symptomatic despite...

2013-02-23 23:01:26

Research from the 2013 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) looked at the effects of polycyclic aromatic hydrocarbon (PAH) exposure on a sample of children in Fresno, California. SAN ANTONIO, TX (PRWEB) February 23, 2013 Outside air pollutants are a known trigger of asthma, the most common chronic disease in children according to the World Health Organization, but whether these pollutants actually cause new cases of asthma is still being...